Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 6/20 | 0.42 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.35 |
| ▸ | ANPEP | P15144 | 2/20 | 0.35 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026886 | 0.81 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL4872186 | 0.79 | PTGS1 (0.44) | PRKCAPTGS1SLC7A11ENPEPANPEP | |
| SCHEMBL3396294 | 0.79 | PTGS1 (0.44) | PRKCAPTGS1SLC7A11ENPEPANPEP | |
| SCHEMBL10130615 | 0.76 | PRKCA (0.65) | PRKCAPRKCEPRKCQPRKCD | |
| Succinic Acid SCHEMBL15323069 | 0.75 | PRKCA (0.40) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL14181781 | 0.73 | PTGS1 (0.43) | PTGS1SLC7A11ENPEPTLR2 | |
| Succinic Acid SCHEMBL15323308 | 0.72 | PRKCA (0.40) | PRKCAPRKCEPRKCQPRKCDTLR2 | |
| SCHEMBL1405394 | 0.71 | LMNA (0.56) | PRKCAPRKCEPRKCQPRKCDTLR2 | |
| SCHEMBL538145 | 0.71 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL2790714 | 0.71 | PRKCA (0.49) | PRKCAPRKCEPRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090220587-A1 | Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands | UNITED STATE ARMY (US) | 2009-09-03 | — | — | US | claimed |
| US-20090220587-A1 | Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands | UNITED STATE ARMY (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220587-A1 | Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands | LDLR, LAMP2, LAMP1 | PRKCA 3265/4885PRKCE 3370/4885PRKCQ 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.